Cell type-associated traits map for the [FetalAdrenalGland_Smooth muscle cell][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [FetalAdrenalGland_Smooth muscle cell]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
2 Hour Glucose | 2-Hour Glucose | ETC | Saxena | 2010 | NA | 15234 | 5.00e-2 | 4.38e-2 |
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 5.00e-2 | 6.02e-3 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-3 | 6.45e-5 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-4 | 5.78e-5 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-5 | 9.62e-3 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 7.21e-3 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 7.37e-5 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 1.00e-4 | 1.59e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 5.00e-2 | 4.56e-2 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 5.00e-2 | 9.82e-4 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-2 | 1.41e-2 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 2.29e-2 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 3.10e-4 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 5.00e-2 | 2.29e-2 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 3.10e-4 |
Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 5.00e-2 | 3.04e-3 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 5.00e-2 | 3.78e-2 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 1.00e-3 | 9.40e-3 |
Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-5 | 3.47e-2 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 3.69e-2 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 1.00e-2 | 3.85e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 5.00e-2 | 8.01e-3 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 5.00e-2 | 2.51e-2 |
Alcohol Consumption | Alcohol Consumption Men Dichotomous | MTC | Schumann | 2016 | NA | 26991 | 1.00e-2 | 2.58e-2 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 4.17e-3 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 3.31e-2 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-2 | 7.66e-3 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 5.00e-2 | 4.28e-3 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-2 | 4.06e-3 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 3.17e-2 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-3 | 2.70e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 1.09e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 1.00e-2 | 6.80e-3 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-2 | 1.07e-2 |
Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-3 | 1.56e-2 |
Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.17e-2 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 1.00e-3 | 3.77e-2 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 5.00e-2 | 4.36e-3 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 1.00e-2 | 1.48e-3 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 1.00e-3 | 2.50e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 5.22e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 6.11e-6 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.11e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 3.61e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.17e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.10e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.56e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 3.46e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 2.38e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 4.52e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.75e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.75e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.09e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.26e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 9.80e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.56e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 7.72e-5 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 6.64e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 2.22e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.68e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.14e-4 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.05e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.59e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.46e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.90e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 1.92e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.60e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.00e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 3.85e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.66e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.42e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.40e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 1.54e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.64e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.29e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 5.78e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 2.74e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 4.81e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-3 | 4.26e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 1.00e-3 | 2.23e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 60 And More | MTC | Medina-Gomez | 2018 | NA | 22504 | 1.00e-2 | 3.62e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-3 | 1.94e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-4 | 3.71e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 5.00e-2 | 2.75e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-2 | 2.11e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 3.40e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-2 | 1.51e-2 |
Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 5.00e-2 | 3.87e-2 |
Coronary Artery Disease | Coronary Artery Disease Recessive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 4.02e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 4.97e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 2.73e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-3 | 7.21e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 1.11e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 1.04e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-3 | 2.30e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 2.33e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 1.45e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 1.17e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 6.89e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 8.36e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-3 | 1.17e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7432 | 1.00e-3 | 4.37e-2 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 2.42e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease | ETC | Pattaro | 2016 | 12385 | 104780 | 5.00e-2 | 2.48e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 5.00e-2 | 4.85e-2 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 1.26e-2 |
Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 1.00e-2 | 1.88e-2 |
Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.16e-2 |
Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.13e-3 |
Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.00e-4 |
Facial Shape | Mod14 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.07e-2 |
Facial Shape | Mod16 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.22e-2 |
Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.41e-3 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.32e-2 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.38e-3 |
Facial Shape | Mod2 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.16e-2 |
Facial Shape | Mod2 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.59e-2 |
Facial Shape | Mod22 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.19e-3 |
Facial Shape | Mod22 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.40e-2 |
Facial Shape | Mod22 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.22e-2 |
Facial Shape | Mod24 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.74e-2 |
Facial Shape | Mod25 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.97e-2 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.88e-3 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.61e-3 |
Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 6.67e-4 |
Facial Shape | Mod3 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.68e-3 |
Facial Shape | Mod30 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.87e-2 |
Facial Shape | Mod32 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.51e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.62e-4 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 6.87e-3 |
Facial Shape | Mod38 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.87e-2 |
Facial Shape | Mod38 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 9.59e-3 |
Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 5.90e-3 |
Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.28e-2 |
Facial Shape | Mod45 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 3.59e-2 |
Facial Shape | Mod48 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.88e-2 |
Facial Shape | Mod50 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.99e-2 |
Facial Shape | Mod51 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.63e-2 |
Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.93e-2 |
Facial Shape | Mod56 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.10e-2 |
Facial Shape | Mod56 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.04e-2 |
Facial Shape | Mod59 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.21e-2 |
Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.86e-3 |
Forced Expiratory Volume | Forced Expiratory Volume | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 7.26e-3 |
Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 4.80e-2 |
Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-4 | 4.44e-2 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 3.83e-3 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-2 | 8.84e-5 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-3 | 3.15e-2 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-5 | 3.41e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 3.02e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 1.00e-3 | 1.89e-2 |
Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 3.22e-2 |
Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 4.54e-2 |
Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 1.36e-2 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 3.66e-2 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 1.00e-3 | 3.46e-2 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.33e-3 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 1.49e-2 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 3.62e-4 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 9.12e-3 |
Ischaemic Stroke | Small Vessel Disease | MTC | Traylor | 2012 | 2275 | 12285 | 1.00e-3 | 5.36e-3 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 4.15e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-3 | 1.56e-2 |
Kidney Function | Rapid Decline | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 1.93e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-2 | 2.64e-2 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 2.38e-2 |
Lean Body Mass | Whole Body Lean Mass | MTC | Zillikens | 2017 | NA | 38292 | 1.00e-2 | 4.99e-2 |
Lean Body Mass | Whole Body Lean Mass | MTC | Zillikens | 2017 | NA | 38292 | 1.00e-3 | 2.63e-2 |
Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-3 | 3.16e-2 |
Loneliness | Loneliness | MTC | Gao | 2017 | NA | 6924 | 1.00e-3 | 2.59e-2 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-3 | 3.41e-2 |
Longevity | Age 90 Or Greater | MTC | Deelen | 2014 | 5406 | 15112 | 1.00e-2 | 4.70e-2 |
Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 7.22e-3 |
Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 4.12e-2 |
Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 1.45e-2 |
Pubertal Anthropometrics | Late Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 4.86e-2 |
Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 5.00e-2 | 4.43e-3 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 2.02e-3 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 5.00e-2 | 1.53e-2 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-2 | 1.21e-2 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-3 | 1.12e-3 |
Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 5.00e-2 | 2.09e-2 |
Stroke (ischemic) | All Ischemic Stroke | MTC | Traylor | 2017 | 12389 | 62004 | 5.00e-2 | 2.09e-2 |
Stroke (ischemic) | Cardioembolic Stroke | MTC | Traylor | 2017 | 2365 | 62004 | 1.00e-2 | 2.04e-2 |
Stroke (ischemic) | Cardioembolic Stroke | MTC | Traylor | 2017 | 2365 | 62004 | 1.00e-3 | 2.58e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 1.68e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-2 | 4.02e-3 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-3 | 6.59e-3 |
Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 6.72e-3 |
Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 6.57e-3 |
Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 9.72e-3 |
Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 2.62e-2 |
Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 3.31e-2 |
Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 8.67e-3 |
Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 3.88e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 2.39e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 8.84e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 2.73e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 3.85e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 2.47e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 3.92e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 1.29e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 1.52e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 4.16e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 2.10e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 2.91e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 4.20e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 3.64e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 4.51e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 3.10e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 1.41e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-5 | 1.05e-2 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 5.28e-3 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 3.83e-2 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 4.64e-2 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 9.50e-3 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 3.57e-4 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 2.47e-3 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 3.77e-2 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 2.98e-2 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 4.50e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 2.27e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 9.21e-3 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-2 | 2.13e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-5 | 1.79e-2 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-2 | 3.63e-2 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 5.00e-2 | 2.23e-2 |
Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 5.00e-2 | 2.83e-2 |
Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 1.00e-2 | 2.12e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 3.18e-3 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 1.26e-3 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.48e-4 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 2.53e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 3.47e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 3.48e-4 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-2 | 6.06e-4 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-3 | 3.71e-2 |
Sleep | Sleep time to midpoint | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 2.48e-2 |
Facial attractiveness | Facial attractiveness of males, male raters | ETC | Hu | 2019 | NA | 1792 | 5.00e-2 | 3.54e-2 |
Facial attractiveness | Facial attractiveness of males, male raters | ETC | Hu | 2019 | NA | 1792 | 1.00e-2 | 1.48e-2 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 3.58e-2 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 5.00e-2 | 1.83e-2 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 5.00e-2 | 2.64e-2 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 2.92e-4 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 3.30e-2 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 4.66e-2 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 1.40e-3 |
Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 5.00e-2 | 7.18e-3 |
Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 1.00e-2 | 1.32e-3 |
Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 5.00e-2 | 2.14e-2 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 3.59e-2 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 5.00e-2 | 5.94e-3 |
Hippocampal volume | Total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.62e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.25e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.73e-2 |
Hippocampal volume | Hippocampal tail volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.79e-2 |
Brain volume | Dentate gyrus molecular layer volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.76e-3 |
Brain volume | Dentate gyrus molecular layer volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 3.83e-2 |
Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.14e-2 |
Hippocampal volume | Hippocampal subfield CA4 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.95e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.92e-3 |
Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 1.28e-2 |
Subiculum volume | Subiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.41e-2 |
Subiculum volume | Subiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 7.19e-3 |
Parasubiculum volume | Presubiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 6.23e-3 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 5.00e-2 | 5.68e-3 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-2 | 1.63e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 3.84e-3 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-4 | 2.11e-3 |
Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 1.00e-2 | 4.29e-2 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 5.00e-2 | 6.36e-3 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-2 | 9.96e-3 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-3 | 2.68e-2 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-4 | 4.00e-2 |
Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-2 | 4.12e-3 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-2 | 6.74e-3 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-3 | 2.40e-2 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 3.86e-3 |
Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 5.00e-2 | 8.81e-3 |
Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 1.00e-2 | 1.96e-2 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-2 | 3.43e-2 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 2.53e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 1.47e-3 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 1.27e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-3 | 8.64e-3 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 5.00e-2 | 4.39e-2 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-2 | 9.23e-3 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 5.00e-2 | 1.23e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-2 | 2.82e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-3 | 2.93e-3 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-4 | 1.62e-4 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-5 | 3.59e-4 |
Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 1.35e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 2.66e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 3.14e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-3 | 5.95e-3 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 7,834 | 15,258 | 5.00e-2 | 1.17e-2 |
Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 5.00e-2 | 3.82e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 3.65e-3 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-4 | 3.41e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 1.05e-4 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 2.61e-5 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 4.21e-4 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 1.46e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 4.12e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-3 | 4.19e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-4 | 4.02e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-5 | 9.27e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 3.60e-4 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 6.23e-4 |
Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 5.00e-2 | 3.54e-2 |
Uterine fibroids | Uterine fibroids | ETC | Gallagher CS | 2019 | 20,406 | 223,918 | 1.00e-3 | 3.83e-2 |
BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 1.65e-3 |
BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 5.00e-2 | 7.45e-3 |
PD | Parkinson's disease in GBA mutation carriers | ETC | Blauwendraat C | 2020 | 1,588 | 7,584 | 5.00e-2 | 1.10e-2 |
PD | Parkinson's disease in GBA mutation carriers | ETC | Blauwendraat C | 2020 | 1,588 | 7,584 | 1.00e-2 | 2.36e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 3.30e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 1.70e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 4.69e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-4 | 2.03e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 2.60e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-2 | 4.79e-3 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-3 | 6.85e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 2.99e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.30e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 2.54e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 4.55e-7 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 2.00e-7 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 3.64e-5 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 3.35e-7 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 2.23e-6 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 5.00e-2 | 2.86e-4 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-2 | 3.03e-3 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-3 | 1.07e-4 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-4 | 3.83e-2 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-5 | 4.67e-2 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 5.00e-2 | 6.35e-5 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-2 | 1.31e-3 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-3 | 1.96e-3 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 5.00e-2 | 3.40e-3 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-2 | 4.05e-3 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-3 | 2.35e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 5.00e-2 | 1.24e-3 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-2 | 2.83e-3 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-3 | 9.24e-3 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-4 | 4.68e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 3.28e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-4 | 5.37e-3 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 5.00e-2 | 2.35e-2 |
COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 5.00e-2 | 1.12e-2 |
COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-2 | 1.61e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.